Rosetta Genomics—working on test for mesothelioma—to buy lab in Bensalem, Pennsylvania for $2.9 million
Rosetta Genomics has agreed to acquire Parkway Clinical Laboratories, a privately held CLIA-certified lab, for $2.9 million and an additional $300,000. For Rosetta, an Israel-based company, the acquisition would help expedite development and validation of its first microRNA-based diagnostic tests. These tests will differentiate between mesothelioma and adenocarcinoma and between squamous versus non-squamous non-small cell lung cancer. Rosetta plans to develop and validate these tests at Parkway’s facilities in Bensalem, Pa. Parkway employees will join Rosetta, including Raza Bokhari, chairman, president and CEO of Parkway. He will become chief development officer of Rosetta at the close of the acquisition.
For the full story, go to GenomeWeb Daily News.
![[Information package]](http://www.mesotheliomanews.com/wp-content/themes/biromeso/images/infopack.jpg)
